Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Thurner, L. and Poeschel, V. and Haioun, C. and Houot, R. and Gaulard, P. and Molina, T. and Rosenwald, A. and Andre, M. and Hoffmann, J. and Dreyling, M. and Casasnovas, O. and Maisonneuve, H. and Tilly, H. and Illmer, T. and Mayer, S. and Kirchen, H. and La Rosee, P. and Loeffler, M. and Ziepert, M. and Altmann, B. and Held, G. (2020) Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020, Virtuell.

Full text not available from this repository.

Item Type:	Conference or Workshop Item (Speech)
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User:	Petra Gürster
Date Deposited:	20 Apr 2021 05:48
Last Modified:	20 Apr 2021 05:48
URI:	https://pred.uni-regensburg.de/id/eprint/43691

Actions (login required)

View Item